BACKGROUND: Individuals infected with both HIV and hepatitis C virus (HCV) have shown impaired performance on different neuropsychological (NP) tests; however, whether coinfected individuals with controlled HIV and minimal liver damage in the era of antiretroviral therapy have impairment is understudied. METHODS: Nineteen HCV monoinfected, 17 HIV/HCV coinfected, and 17 control male participants were evaluated for depression, attention, executive function, information processing, fine motor speed, and verbal/visual learning/memory. Eleven controls and 14 HIV monoinfected participants with controlled viral load from a previous study were also included for comparison. At time of testing, participants were not using drugs or alcohol and did not have cirrhosis. A global deficit score (GDS) was calculated from 7 domains of NP tests and alterations in specific domains were determined. RESULTS: HIV/HCV subjects had a higher depression score (11.1 ± 7.5) than controls (5.4 ± 4.1, P = 0.010) and a higher GDS score (0.77 ± 0.47) than HCV (0.46 ± 0.34, P = 0.036), HIV (0.45 ± 0.36, P = 0.008), and controls (0.30 ± 0.29, P = 0.001). Coinfection was associated with worse scores in attention working memory (P =0.007), executive function (P = 0.01), fine motor function (P = 0.011), verbal learning/memory (P < 0.001), and visual learning/memory (P < 0.001) compared to controls. Within the HCV group, viral load was associated with lower attention, executive function, and information processing speed and positively with GDS. CONCLUSIONS: Coinfection significantly increased the risk of cognitive impairment in subjects with controlled HIV viral loads. In HCV monoinfected but not coinfected subjects, HCV viral load correlated with worsening GDS, suggesting different pathways for NP impairment.
BACKGROUND: Individuals infected with both HIV and hepatitis C virus (HCV) have shown impaired performance on different neuropsychological (NP) tests; however, whether coinfected individuals with controlled HIV and minimal liver damage in the era of antiretroviral therapy have impairment is understudied. METHODS: Nineteen HCV monoinfected, 17 HIV/HCV coinfected, and 17 control male participants were evaluated for depression, attention, executive function, information processing, fine motor speed, and verbal/visual learning/memory. Eleven controls and 14 HIV monoinfected participants with controlled viral load from a previous study were also included for comparison. At time of testing, participants were not using drugs or alcohol and did not have cirrhosis. A global deficit score (GDS) was calculated from 7 domains of NP tests and alterations in specific domains were determined. RESULTS: HIV/HCV subjects had a higher depression score (11.1 ± 7.5) than controls (5.4 ± 4.1, P = 0.010) and a higher GDS score (0.77 ± 0.47) than HCV (0.46 ± 0.34, P = 0.036), HIV (0.45 ± 0.36, P = 0.008), and controls (0.30 ± 0.29, P = 0.001). Coinfection was associated with worse scores in attention working memory (P =0.007), executive function (P = 0.01), fine motor function (P = 0.011), verbal learning/memory (P < 0.001), and visual learning/memory (P < 0.001) compared to controls. Within the HCV group, viral load was associated with lower attention, executive function, and information processing speed and positively with GDS. CONCLUSIONS: Coinfection significantly increased the risk of cognitive impairment in subjects with controlled HIV viral loads. In HCV monoinfected but not coinfected subjects, HCV viral load correlated with worsening GDS, suggesting different pathways for NP impairment.
Authors: Catherine L Carey; Steven Paul Woods; Raul Gonzalez; Emily Conover; Thomas D Marcotte; Igor Grant; Robert K Heaton Journal: J Clin Exp Neuropsychol Date: 2004-05 Impact factor: 2.475
Authors: Daniel M Forton; Howard C Thomas; Christine A Murphy; Joanna M Allsop; Graham R Foster; Janice Main; Keith A Wesnes; Simon D Taylor-Robinson Journal: Hepatology Date: 2002-02 Impact factor: 17.425
Authors: Mary Pat McAndrews; Karl Farcnik; Peter Carlen; Andrei Damyanovich; Mirela Mrkonjic; Susan Jones; E Jenny Heathcote Journal: Hepatology Date: 2005-04 Impact factor: 17.425
Authors: Howard Crystal; Inna Kleyman; Kathryn Anastos; Jason Lazar; Mardge Cohen; Chenglong Liu; Leigh Pearce; Elizabeth Golub; Victor Valcour; Ann Ho; Howard Strickler; Marion Peters; Andrea Kovacs; Susan Holman; Mary Jeanne Kreek; Jennifer Manly Journal: J Acquir Immune Defic Syndr Date: 2012-02-01 Impact factor: 3.731
Authors: Karl Goodkin; Eric N Miller; Christopher Cox; Sandra Reynolds; James T Becker; Eileen Martin; Ola A Selnes; David G Ostrow; Ned C Sacktor Journal: Lancet HIV Date: 2017-07-14 Impact factor: 12.767
Authors: Sérgio Monteiro de Almeida; Ana Paula de Pereira; Maria Lucia Alves Pedroso; Clea E Ribeiro; Indianara Rotta; Bin Tang; Anya Umlauf; Donald Franklin; Rowan G Saloner; Maria Geny Ribas Batista; Scott Letendre; Robert K Heaton; Ronald J Ellis; Mariana Cherner Journal: J Neurovirol Date: 2018-03-07 Impact factor: 2.643
Authors: Ajay R Bharti; Allen McCutchan; Reena Deutsch; Davey M Smith; Ronald J Ellis; Mariana Cherner; Steven P Woods; Robert K Heaton; Igor Grant; Scott L Letendre Journal: Clin Infect Dis Date: 2016-10-28 Impact factor: 9.079
Authors: Arpi Minassian; Brook L Henry; Steven Paul Woods; Florin Vaida; Igor Grant; Mark A Geyer; William Perry Journal: J Int Neuropsychol Soc Date: 2013-04-03 Impact factor: 2.892
Authors: Victor G Valcour; Leah H Rubin; Mary U Obasi; Pauline M Maki; Marion G Peters; Susanna Levin; Howard A Crystal; Mary A Young; Wendy J Mack; Mardge H Cohen; Christopher B Pierce; Adaora A Adimora; Phyllis C Tien Journal: J Acquir Immune Defic Syndr Date: 2016-07-01 Impact factor: 3.731